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sion: The purpose-designed battery was adequate for the 
screening of cognitive dysfunction in MS patients. The bet-
ter accuracy of the single-task approach might reflect MS 
heterogeneity.  Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 As a central nervous system disease, multiple sclerosis 
(MS) is often accompanied by deficits in processing 
speed, attention, recent memory and other cognitive do-
mains  [1] . Cognitive dysfunction in MS is associated with 
unemployment  [2, 3] and constitutes a major focus of in-
terest for both diagnostic and treatment purposes  [4] . 
However, cognitive performance displays a considerable 
level of variability, and there is some discrepancy about 
prevalence and methodology of assessment.
 Cognitive evaluation should be conditioned not only 
by the nature of the underlying process, but also by the 
purpose of assessment. Comprehensive neuropsycholog-
 Key Words 
 Cognitive function screening   Multiple sclerosis 
 Abstract 
 Background/Aims: Cognitive dysfunction is a major handi-
cap in multiple sclerosis (MS). Its prevalence varies due to 
disease heterogeneity and methodological issues. A neuro-
psychological battery of intermediate size was designed for 
and explored in the screening of cognitive dysfunction in MS 
patients.  Methods: The battery was administered to a hos-
pital-based sample of 191 MS patients and 50 matched con-
trols. Eleven test scores measuring verbal fluency, verbal 
learning, attention, calculation and visuoperceptual ability 
were selected on the basis of sensitivity and lack of redun-
dancy. Two alternative approaches were compared for diag-
nosis of cognitive dysfunction based, firstly, on the number 
of failed tasks, and secondly, on a single standardized global 
score.  Results: The approach based on the number of failed 
tasks discriminated better than did the global approach be-
tween patients and controls. Using a cutoff of two altered 
scores, a cognitive dysfunction prevalence of 34% was ob-
tained. The score yielded after summing errors in all tests 
was the most frequently altered and proved particularly
useful for detecting minimally impaired patients.  Conclu-
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ical batteries are sensitive, but not affordable for screen-
ing purposes. Moreover, extensive batteries may not be 
suitable for severely impaired or poorly educated patients. 
On the other hand, short mental-status tests lack sensi-
tivity  [5, 6] and fail to offer a minimally detailed picture 
of the altered functions  [7] .
 Intermediate-length batteries have emerged as a rea-
sonable compromise between sensitivity and cost, and 
are increasingly used in both clinical and research con-
texts  [1, 6–9] . Nevertheless, the way in which the diagnos-
tic value of these batteries can be optimized has not re-
ceived sufficient attention. Traditionally, the prevalence 
and severity of cognitive dysfunction have been estab-
lished on the basis of the number of altered test scores  [1, 
6, 8] . Alternatively, if a unitary attention and processing 
speed failure in MS is assumed, a single composite score 
might be more appropriate  [10, 11] .
 We developed an intermediate-length neuropsycho-
logical battery focusing on the most frequently altered 
cognitive functions in MS. Sensitivity, briefness and ease 
of administration were prioritized. The battery was ad-
ministered to a hospital-based MS cohort and matched 
control subjects. In order to optimize diagnostic efficien-
cy, several cognitive scores were explored and two alter-
native diagnostic approaches (multiple scores vs. single 
composite score) were compared. 
 Patients and Methods 
 Patients 
 The study population consisted of 191 MS patients randomly 
selected for the second wave of the Madrid Demyelinating Dis-
ease Group (Grupo de Enfermedades Desmielinizantes de Ma-
drid, GEDMA) study, a survey of physical, neuropsychological 
and social issues of MS in a cohort of 371 patients recruited from 
13 hospitals in Madrid. MS patients were recruited by random 
sampling of MS databases at each hospital. Demographic and 
clinical characteristics of the inception cohort were similar to 
those described in population-based MS studies. The GEDMA 
study began in 2000 and the cohort was followed up over 2 years. 
Fuller details of the sample design and eligibility criteria have 
been published elsewhere  [12] . Briefly, a senior neurologist with 
expertise in MS (J.B.-L.) reviewed patient charts to determine 
clinical characteristics and eligibility. All patients met criteria for 
clinically confirmed MS  [13] and were free from any MS exacer-
bation at the time of assessment. Disease duration was defined as 
the period between symptom onset and assessment date. Neuro-
logical impairment and disability were rated according to the Ex-
panded Disability Status Scale (EDSS)  [14] . Current medications 
were also recorded. 
 The second wave of the GEDMA study was implemented in 
two stages: in the first of these, a quality of life instrument  [15] , a 
brief screening tool for cognitive performance  [16] and a fatigue 
scale were administered  [17] ; in the second stage, subjects were 
visited by a trained neuropsychologist who performed formal 
neuropsychological (see the neuropsychological battery below) 
and psychiatric assessments. Neuropsychologists were blind to 
clinical charts and to first-step measurements. They established 
dementia and psychiatric diagnosis in accordance with the Diag-
nostic and Statistical Manual of Mental Disorders (ed. 4, DSM-
IV) criteria  [18] . All patients gave their written informed consent 
before assessment, and the Móstoles General Hospital Ethics 
Committee approved of all aspects of the study.
 Control Subjects 
 Fifty subjects were matched to patients by age, sex and educa-
tion. Controls were chosen from among researchers’ acquain-
tances and health workers. Subjects in the control group reported 
no relevant cognitive complaints, suffered from no psychiatric 
illnesses and had no systemic or neurological conditions that 
could affect cognition.
 Neuropsychological Battery 
 The following cognitive tests were chosen on the basis of ex-
pected patterns  [1, 2] , personal experience and study objectives. 
Tests were usually administered in one session, in the same order 
as described below.
 Verbal Fluency. Since processing speed and mental control are 
frequently affected in MS patients, three verbal fluency tasks were 
included in the battery. For semantic fluency, participants were 
asked to name as many different animals as they could  [19] . Pho-
nemic fluency was assessed using a variant of the Controlled Oral 
Word Association Test  [20] . In our task, participants were in-
structed to generate as many different words as possible begin-
ning with the letter ‘p’. Participants were instructed not to use 
proper nouns or repeat the same word with a different ending. As 
a new test in MS, we also asked subjects to generate as many dif-
ferent words as possible that did not contain the letter ‘e’. Since 
this requires extra effort, over and above that demanded by the 
common task of retrieving names, this test should be particularly 
sensitive to cognitive dysfunction in MS patients. For the three 
verbal fluency tasks, each response was recorded verbatim for
60 s. Intrusions (i.e., responses different from target) and perse-
verations (i.e., intrusions repeated during the task) were also re-
corded.
 Verbal Learning. The Selective Reminding Test was used to 
evaluate subjects’ ability to remember a list of 16 unrelated words, 
to learn these words over three trials, and to recall these words 
after a 30-min delay. Subjects were first presented with cards of 
four words each. During the acquisition phase, subjects were 
asked to read the four words aloud and then say which word cor-
responded to different semantic categories. Free and total (i.e., 
free plus cued) recall, both immediately and after 30 min, were 
subjected to analysis  [21] . Intrusions (i.e., mistakes corresponding 
to the same or a different category) as well as perseverations (i.e., 
repeated intrusions) were recorded. 
 Selective Attention. A variant of the Stroop Color and Word 
Test was used to assess selective attention, perceptual interfer-
ence, and information processing speed. The traditional test con-
sists of reading words, naming colors, and then naming the ink 
color of words describing colors, where such words are printed in 
a nonmatching colored ink  [22] . Due to time constraints, only the 
interference task was administered, the performance of which
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appears to be particularly impaired in MS  [23] . Subjects were
instructed to correct their mistakes in all cases. In addition to to-
tal correct responses in 45 s, inhibition failures (i.e., reading the 
word instead of stating the color of the ink) and perseverations 
(i.e., a new inhibition failure following subject or examiner cor-
rection) were recorded.
 Serial Additions.  The Paced Auditory Serial Addition Test is a 
commonly used procedure in MS that combines elements of both 
calculation and working memory. The test requires patients to 
add 60 pairs of randomized digits in such a way that each is add-
ed to the immediately preceding digit. A practice task of 11 digits 
was given first. Digits were presented via audiotape at 2-second 
intervals. The standard score for this task is the number of correct 
responses at each stimulus presentation rate  [24] . In addition, 
omissions (i.e., skipped digits), interference errors (i.e., addition 
to the previous sum or to former digit) and other errors (e.g., cal-
culation errors) were registered.
 Visuoperceptual Ability. The Visual Object and Space Percep-
tion Battery cube analysis test was used to assess visuoperceptual 
ability. This task consists of determining the number of solid 
cubes (or ‘blocks’) in a picture. After two training items, the num-
ber of correct answers out of 10 was recorded  [25] .
 Analyses 
 Descriptive statistics were used to summarize the demograph-
ic, clinical and cognitive characteristics of the two study groups 
and MS clinical subgroups. Differences between groups were an-
alyzed using the t test,   2 -test and one-way analysis of variance. 
All tests for statistical comparisons were performed bilaterally. 
Redundancy between cognitive scores was investigated in the MS 
group using Pearson correlation coefficients. A set of cognitive 
scores was selected for cognitive diagnosis on the basis of sensitiv-
ity, comprehensiveness and lack of redundancy. 
 Two alternative approaches were explored for cognitive diag-
nosis: as a traditional approach, the number of failed cognitive 
scores was computed, and as an alternative, a global standardized 
(z) score was calculated for each participant. This global z score 
was the mean of z scores in the selected cognitive scores. The 
means and standard deviations of the control group were used to 
obtain z scores. Normality assumptions were explored in the dis-
tribution of cognitive scores, and cutoffs for abnormality were 
selected accordingly. The prevalence of cognitive dysfunction in 
MS patients was obtained by subtracting prevalence among con-
trols from prevalence among MS patients. All statistical analyses 
were performed using the SPSS version 11.5 computer software 
program (SPSS Inc., Chicago, Ill., USA).
 Results 
 The demographic and clinical characteristics of pa-
tients and controls are shown in  table 1 . Patients who par-
ticipated in the cognitive study did not differ significant-
ly from the original GEDMA cohort in terms of age, sex 
and clinical profile. As in the original cohort, patients 
suffering from progressive MS were older, had a longer 
disease duration and displayed a poorer functional and 
fatigue status (comparisons between this study and the 
inception GEDMA cohort not shown)  [12] . Patients 
ranged in age from 20 to 71 years (median 38), disease 
duration ranged from 3 to 34 years (median 12), and 
EDSS scores ranged from 0 to 9 (median 3.5) ( table 1 ). 
 Cognitive performance for the different study groups 
is shown in  table 2 . Nine patients failed to complete one 
or more tests (one in the case of 7 patients, three in the 
case of 2 patients) owing to important cognitive impair-
ments. Nine patients (4.7%) were deemed to be demented. 
As a group, MS patients performed systematically worse 
than did controls. Among MS patients, those suffering 
from progressive disease performed worse. In general, 
while cognitive scores in primary progressive (PP) and 
secondary progressive (SP) MS were comparable, they 
were significantly poorer than cognitive scores registered 
by relapsing-remitting (RR) patients, which lay between 
the progressive MS and control groups. Two exceptions 
to this pattern should be noted: firstly, RR patients per-
formed on a par with controls in the visual analysis task; 
and secondly, save for omissions in the serial additions 
task (which followed the general pattern described), no 
clear differences between MS subgroups were in evidence 
with respect to the type or number of errors committed 
(descriptive data of errors in the different tests not 
shown). 
 The performance pattern in the three verbal fluency 
tasks was substantially similar among MS patients and 
controls. As predicted, fewer correct responses were ob-
tained in the most demanding task (i.e., ‘words without 
e’), but this phenomenon was also observed for the nor-
mal subjects. Moreover, a similar decreasing correct-re-
sponse rate pattern was observed for both MS and control 
subjects in the three verbal fluency tasks (responses were 
recorded at 15-second intervals; data not shown). Since 
differences between MS patients and normal subjects 
were most consistently observed when the total number 
of correct responses was used, this score was retained for 
the purpose of cognitive diagnosis. Correlations between 
the three verbal fluency scores selected were moderate, 
with r ranging from 0.594 to 0.694.
 The verbal learning results showed that the main dif-
ferences between patients and controls were in free recall. 
These differences became attenuated after cued recall 
( table 2 ). Memory scores were highly correlated, with 
Pearson coefficients ranging from 0.599 (‘free recall-1’, 
‘total recall-3’) to 0.898 (‘total recall-3’, ‘total recall, de-
layed’) (acquisition and error scores, which offered much 
lower correlation coefficients, are not included here). 
Since maximum differences between patients and con-
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p (for MS 
subgroups)
Age, years 40.2 (11.7) 40.1 (10.5) 37.5 (9.3)a, b 49.1 (13.8)a 43.7 (9.9)b 0.000
Women, % 72.0 71.2 74.4 71.4 63.5 0.342
Education, % 0.796
None 2.0 3.7 2.4 7.1 5.8
Primary 40.0 39.8 42.4 35.7 34.6
Intermediate 36.0 36.1 36.8 35.7 34.6
University 22.0 20.4 18.4 21.4 25.0
Evolution, years NA 12.3 (6.6) 11.5 (6.5)c 12.1 (6.5) 14.4 (6.8)c 0.026
EDSS 0 3.9 (2.4) 2.5 (1.7)a, a 6.3 (1.0)a 6.4 (1.0)a 0.000
MMSE NP 26.4 (2.7) (n = 186) 26.7 (2.6) 26.2 (2.9) 25.8 (3.0) 0.185
Dementia, % 0 4.7 1.6 7.1 11.5 0.016
Psychiatric morbidity, % 0 44.6 (n = 186) 42.6 38.5 51.0 0.540
On interferon, % 0 64.4 65.6 35.7 69.2 0.060
Values are shown as mean (SD), unless otherwise indicated. a p < 0.0005; b p < 0.005; c p < 0.05 (for differences between MS sub-
groups with the same superscript letter, using Scheffé’s test). MMSE = Mini-Mental State Examination Test; NA = not applicable;
NP = not performed.













Animals 20.1 (4.6) 17.1 (6.3) 0.000 18.2 (6.1)d 14.2 (5.5) 15.3 (6.4)d 0.003
Words beginning with p 15.8 (5.0) 12.6 (5.2) 0.000 13.6 (5.2)b 11.1 (3.7) 10.7 (5.1)b 0.002
Words without e1 13.4 (4.5) 10.1 (4.5) 0.000 10.9 (4.3)c 8.1 (4.4) 8.6 (4.5)c 0.003
Verbal learning2
Free recall-3 (16) 11.0 (2.6) 9.2 (3.1) 0.000 9.6 (2.8) 8.4 (3.4) 8.4 (3.7) 0.063
Total recall-3 (16) 15.1 (1.6) 14.1 (2.6) 0.002 14.4 (2.1) 14.2 (3.1) 13.4 (3.5) 0.090
Free recall, delayed (16) 11.4 (2.4) 9.3 (3.6) 0.000 9.9 (3.3)c 8.3 (4.1) 8.1 (3.9)c 0.004
Total recall, delayed (16) 14.6 (1.7) 13.7 (2.9) 0.003 14.0 (2.4) 13.5 (3.2) 12.8 (3.7) 0.062
Selective attention3
Stroop, interference task 38.9 (8.5) 32.6 (12.0) 0.000 35.3 (11.3)a, d 26.9 (12.3)d 26.9 (11.2)a 0.000
Serial additions4
PASAT (60) 42.0 (11.8) 33.9 (15.5) 0.000 36.3 (14.9)d 30.1 (13.9) 28.9 (16.2)d 0.010
Visual perception2
VOSP, cube analysis (10) 9.2 (1.2) 9.0 (1.8) 0.452 9.3 (1.3)d, d 7.9 (3.5)d 8.5 (2.1)d 0.003
Errors, n 10.9 (5.8) 18.6 (11.7) 0.000 18.5 (11.2) 18.5 (13.7) 18.6 (12.4) 0.998
Global z score 0.0 (0.7) –0.7 (1.0) 0.000 –0.5 (0.9)b –1.1 (1.2) –1.1 (1.1)b 0.001
Data are shown as mean (SD); maximum scores are shown in parentheses. The number of errors was computed as the sum of
errors in verbal fluency, verbal learning and selective attention tests. a p < 0.0005, b p < 0.005, c p < 0.01, d p < 0.05 (for differences be-
tween MS subgroups with the same superscript letter, using Scheffé’s test). PASAT = Paced Auditory Serial Addition Test; VOSP = 
Visual Object and Space Perception Battery. 
1 n = 190 for MS group. 2 n = 189 for MS group. 3 n = 184 for MS group. 4 n = 190 for MS group.
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trols were obtained in free recall at the third learning tri-
al (‘free recall-3’) and in free delayed recall, these two 
scores were retained for the purpose of cognitive diagno-
sis. Total recall scores (i.e., immediate and delayed total 
recall) were also included to reflect the fact that a consid-
erable proportion of patients achieved normal perfor-
mance once the semantic cue was given.  
 Patients performed significantly worse than control 
subjects both in serial additions and in the Stroop test, 
whereas visuoperceptual ability was only poorer in MS 
patients who presented with progressive clinical course 
( table 2 ). Correlations between serial additions, Stroop, 
visuoperceptual ability and the formerly selected scores 
were low to moderate, ranging from 0.267 (‘VOSP, cube 
analysis’, ‘Stroop, interference task’) to 0.590 (‘Stroop, in-
terference task’, ‘words without e’). Consequently, the 
number of correct responses in serial additions, Stroop 
and cube analysis were selected for cognitive diagnosis.
 Patients and controls alike committed very few errors 
in each individual test, with the exception of omissions 
in the serial addition task. For this reason, Spearman’s 
rather than Pearson’s correlation coefficients were used 
in error analyses. Correlations between error scores were 
very variable, ranging from –0.138 (intrusions in ‘ani-
mals’, perseverations in ‘delayed recall’) to 0.641 (intru-
sions in immediate recall, intrusions in delayed recall). 
This variability was attributed to the low number of er-
rors in most tests. Correlations between errors and cor-
rect responses in the same test were also very variable, 
ranging from –0.672 (‘total recall, delayed’, intrusions in 
delayed recall) to 0.176 (‘free recall, delayed’, persevera-
tions in immediate recall). Again, this variability was at-
tributed to the low number of errors. A lone exception to 
this pattern should be noted: correlation between correct 
additions and omissions in the serial addition test was 
particularly high (r = –0.887). On the assumption that all 
errors in the battery could be due to a common cognitive 
dysfunction factor, a global error score was obtained 
from the sum of errors in all tests, other than serial addi-
tion omissions. Serial addition omissions were not in-
cluded to avoid overweight and redundancy. This final 
‘global error score’ was markedly altered in the MS group, 
was not redundant (Pearson’s r between the global error 
score and the other selected cognitive scores ranged from 
–0.106 to –0.508), and was finally added to the other 10 
scores selected ( table 2 ).
 Four out of 11 selected cognitive scores (‘free recall-3’, 
‘total recall, delayed’, ‘VOSP, cube analysis’ and ‘number 
of errors’), as well as the global z score, displayed a skewed 
distribution in the control group, due to a bigger tail on 
the poor-performance distribution side. Hence, percen-
tiles rather than standard deviations were chosen for de-
termining abnormality. Cognitive dysfunction frequen-
cies according to different cutoffs under both traditional 
and global z score scenarios are shown in  table 3 . A better 
trade-off between abnormal performance in MS patients 
and normal performance in control subjects was obtained 
when the number of failed tasks, rather than the global z 
score, was used. A cutoff of two failed tasks offered the 
best balance, yielding a cognitive dysfunction prevalence 
of 34.4% ( table 3 ). As for the 9 demented patients, their 
number of failed tasks ranged from six (1 patient) to 10
(3 patients). All demented patients had a global z score 
below the 5th percentile. 
 The most frequently abnormal scores in MS patients 
were ‘free recall, delayed’ (27.5%), ‘number of errors’ 
(26.2%) and ‘animals’ (25.7%), whereas the least frequent-
ly abnormal scores were ‘VOSP, cube analysis’ (7.9%), ‘to-
tal recall-3’ (8.5%) and ‘words beginning with p’ (12.0%). 
The corresponding figures for the subgroup of patients 
registering only one or two abnormal scores were: ‘num-
ber of errors’ (37.5%); ‘Stroop, interference task’ (32.1%); 
‘animals’ (26.8); ‘total recall-3’ (0%); ‘free recall-3’ (1.8%); 
and ‘free recall, delayed’ (1.8%).
Table 3. Frequency of abnormal cognitive performance according to diagnostic approach
Number of failed scores (<5th p.) Cutoff in global z score
1 2 3 4 <5th p. <10th p. <25th p. <50th p.
MS group 56.5 42.4 27.2 21.5 14.7 32.5 52.9 83.2
Control group 18.0 8.0 6.0 2.0 4.0 10.0 24.0 50.0
MS minus control 38.5 34.4 21.2 19.5 10.7 22.5 28.9 33.2
Values represent percentages of individuals; n = 191 (MS group) and 50 (control group). Percentiles and global z score were calcu-
lated using control group data as reference. Missing values (MS group) were treated as normal performance. p. = Percentile.
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 An intermediate-length neuropsychological battery 
was successfully administered to a clinic-based sample of 
191 MS patients and 50 matched controls. Applying a 
‘conservative’ criterion of two abnormal scores, the prev-
alence of cognitive dysfunction was 34%, a figure that 
may seem slightly low when compared to previous stud-
ies. This discrepancy could be due to methodological is-
sues. In a recent study, a prevalence of 56% was obtained 
on the basis of eight cognitive scores. However, a more 
‘liberal’ cutoff of one altered score was chosen, and results 
were not corrected for abnormal performance in control 
subjects  [26] . Remarkably, choosing only one abnormal 
score as cutoff and omitting control group correction 
would have yielded an exact correspondence, namely, a 
cognitive dysfunction prevalence of 56%, in our study. 
However, using one failed score as cutoff for cognitive 
dysfunction might lack specificity, in the light of the 18% 
frequency of such an outcome in the control group ( ta-
ble 3 ). In another study, a cutoff of two altered tests was 
used, and 31% of patients were diagnosed as cognitively 
impaired. Patients were slightly less functionally impaired 
and control-group correction was not used  [27] .
 The appropriateness of correcting cognitive dysfunc-
tion frequency with data from a control group lies in the 
fact that low cognitive performance may be due to several 
reasons other than genuine cognitive decline. Subjects 
could perform poorly in response to cognitive testing due 
to lack of motivation, lack of familiarity with testing con-
ditions, and other contingencies. Rao et al.  [1] , after cor-
recting for low performance in control subjects, and using 
an extensive battery (31 cognitive scores), obtained a 43% 
prevalence of cognitive dysfunction in MS. However, ex-
tensive testing may not necessarily lead to a higher fre-
quency of cognitive dysfunction if low performance in 
control subjects is taken into account. Indeed, more than 
10 years after the seminal study by Rao et al.  [1] , it is ear-
lier diagnosis and improvement in treatment that might 
arguably account for the decline in cognitive dysfunction 
prevalence in our sample. Other sources of variability, 
particularly those concerning setting and recruitment 
methodology, may also be responsible for differences in 
the reported frequencies of cognitive dysfunction in MS.
 Rather than determining the prevalence of cognitive 
dysfunction in MS, our study was aimed at optimizing 
cognitive assessment via an intermediate-length battery. 
Although global standardized scores have been used in 
the assessment of cognitive dysfunction in MS, the au-
thors are not aware of former studies directly contrasting 
the two approaches (i.e., global vs. task-specific scores). 
Use of the number of failed tests proved better at discrim-
inating between patients and controls than did a single 
standardized global score ( table 3 ). This finding is in line 
both with a view of MS as a heterogeneous disorder and 
with a modular perspective of brain functioning. A vari-
ety of pathogenic processes would be differentially repre-
sented among individual patients, giving rise to differ-
ences in both lesion topography and quality of cognitive 
manifestations  [28, 29] . 
 Rao’s Brief Repeatable Battery is the most widely used 
battery for detecting cognitive disturbances in MS. A re-
cent clinic-based study, using a cutoff of two altered scores 
and correcting for control group performance, reported a 
prevalence of cognitive dysfunction of 43%. This higher 
prevalence could be attributable to our battery lacking 
enough demanding visuoperceptual tasks (such as visual 
memory and symbol-digit tasks, both present in the Brief 
Repeatable Battery)  [30] . A limitation of our battery resides 
in the fact that only one relatively easy task was used to as-
sess visuoperceptual abilities ( table 2 ). Traditionally, vi-
suoperceptual abilities have been reported to be less fre-
quently altered in MS  [1] . However, 6% of our minimally 
impaired patients failed the visuospatial task and thus the 
possibility of a lack of sensitivity due to visuoperceptual 
underrepresentation remains. The value of having more 
numerous and demanding visuoperceptual tasks in screen-
ing batteries for MS patients warrants further research.
 By way of original contributions, we introduced a de-
manding verbal fluency task, reduced the Stroop test, and 
registered the number of errors in most tests. As a result, 
battery sensitivity and efficiency improved, due to error 
scoring in particular. Most registered errors were intru-
sions, perseverations and interference failures, which can 
be interpreted as a breakdown in mental processes deal-
ing with temporal storage and manipulation of informa-
tion, mainly depending on frontal-subcortical circuitry 
 [31] . Future inclusion of error scores in MS cognitive bat-
teries may increase their sensitivity at a very low cost.
 In conclusion, an intermediate-length battery was ad-
equate for cognitive screening in a large sample of MS 
patients, though advantages vis-à-vis other existing bat-
teries could not be demonstrated. Once positive cases are 
detected, screening should be followed by a comprehen-
sive neuropsychological assessment to better capture MS 
cognitive diversity and plan cognitive and functional re-
mediation. Establishing different patterns and mecha-
nisms of cognitive dysfunction may help approach lesion 
topography and understand the complex biological 
mechanisms of MS.
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